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Abstract: Several publications have focused on the cardiotoxicity of specific classes of haematological therapeutic agents such as antra-
cyclines and cyclofosfamide. Cardiotoxicity of cancer chemotherapeutics is a problem for patients of all ages, but it increases with age. 
Toxicity can also be developed months after the last chemotherapy dose, and late reactions can be seen years later when they present 
new-onset cardiomyopathy. No data are available about the cardiotoxicity of non-chemotherapy agents currently used as preferred ther-
apy for haematological malignancy in elderly. In this review we have provided a summary of the cardiovascular toxic effects produced 
by different drugs and therapeutic agents. Early identification of patients who are at risk for cardiotoxicity should be a primary goal for 
haematologists in the development of personalised antineoplastic therapeutic strategies or interventions. Thus, the discovery of new bio-
markers to identify patients at a high risk for the development of these complications is a high priority. Although targeted therapies such 
as imatinib and anti-CD20 antibody, such as rituximab, are considered less toxic and better tolerated by patients compared with classic 
chemotherapy drugs, certain cardiological complications can be very serious as these agents have been in use for a limited period of time.  
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INTRODUCTION 
 Cardiotoxicity is a frequent side effect of chemotherapeutic 
agents used in haematological malignancies. Chemotherapy-
associated cardiotoxicity varies from transient blood pressure 
and/or electrocardiographic (EKG) changes to more serious events 
such as arrhythmias, myocarditis, pericarditis, myocardial infarction 
and cardiomyopathy, which may end in left ventricular dysfunction 
(LVD) or congestive heart failure (CHF) [1].  
 Since cardiotoxicity is often dose-dependent, it has a serious 
impact on treatment efficacy; cardiac complications of treatment 
lead to reductions in dose and duration of chemotherapy regimens, 
potentially compromising clinical efficacy. In fact, aggressive che-
motherapy has achieved remission in most types of cancers [2] but 
its use is often limited or even prohibited in elderly patients because 
of its cardiotoxicity. In haematological malignancies, anthracyclins-
based chemotherapy has represented the greatest risk for develop-
ment of cardiotoxicity in this setting of patients.  
 The advent of new categories of drugs, like tyrosine-kinase 
inhibitors, proteosome-inhibitors or monoclonal antibodies has 
revolutionized the treatment of many blood cancers, such as chronic 
myeloid leukaemia, lymphoma, myeloma and others. However, 
although targeted therapies are usually better tolerated than chemo-
therapy, certain cardiac complications still remain and they can be 
very serious [3]; moreover, such new drugs are often used in com-
bination with traditional chemotherapy.  
 Early identification of patients who are at risk for cardiotoxicity 
should be a primary goal for haematologists in the development of 
personalized antineoplastic therapeutic strategies or interventions.  
Purpose of this article is to provide a comprehensive review of the 
adverse cardiac events associated with the use of the most common 
(chemo)-therapeutic agents used in haematological elderly patients 
not eligible for Stem Cell Transplantation (SCT), including new 
molecular-targeted drugs, and to provide guidance as how to pre-
vent such effects.  
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A. CHEMOTHERAPY FOR HAEMATOLOGICAL MALIG-
NANCIES 
 Haematological cancers represent a heterogeneous setting of 
diseases that can originate from highly indifferentiated to mature 
cells thus giving diseases different characteristics in terms of clini-
cal presentation as well as response to therapy and prognosis. De-
spite these varieties, analogous chemotherapy has been proven effi-
cacious in clinically different blood cancers that present a common 
origin. In Table 1 type and duration of the most common therapeu-
tic protocol for treating acute and chronic myeloid and lymphoid 
neoplasm of adults are reported.  
ANTHRACYCLINES 
1. Pathogenesis 
 Anthracyclines have been extensively used for many years to 
treat a wide spectrum of haematologic malignancies and solid tu-
mours [4]. The anthracyclines, doxorubicin and daunorubicin, are 
cytostatic antibiotics isolated from fungi belonging to the species 
Streptomyces. Anthracyclines, such as doxorubicin, and daunorubi-
cin, continue to be some of the most active cytotoxic agents avail-
able and have broad activity against a variety of cancers, including 
acute myeloid and lymphoid leukaemias and solid tumours, such as 
lymphoma, sarcoma and breast cancer [5-7]. Daunorubicin has 
demonstrated activity against acute lymphocytic leukaemia and 
acute myeloid leukaemia. 
 Anthracycline-induced cardiotoxicity is categorised by the time 
of presentation as acute, early-onset or late-onset [8, 9]. In acute 
anthracycline cardiotoxicity, symptoms manifest within hours or 
days of administration, often presenting as disturbances in intracar-
diac conduction and arrhythmias [10, 11]. One of the best predic-
tors of cardiotoxicity is the total cumulative dose of anthracycline 
[12, 13]; generally, doses of > 400 mg/m
2
 are associated with the 
greatest risk of cardiac injury. The incidence of doxorubicin-
induced early HF is almost 3% at a cumulative dose of 400 mg/m
2
, 
7% at a dose of 550 mg/m2 and 18% at 700 mg/m2 [14, 15]. In 
addition to the total cumulative dose, the incidence of acute and 
chronic cardiotoxicity may depend on the rate of anthracycline 
administration during each session [16], the schedule of delivery 
[17], the type of anthracycline used [18] and additional underlying 
risk factors, such as younger age in children and an age of > 65 
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years in adults, African-American ancestry, female sex and trisomy 
21 [19].  
 The cause of anthracycline-induced cardiotoxicity is probably 
multifactorial. Free radical-mediated myocyte damage is one of the 
most thoroughly studied mechanisms by which anthracyclines have 
been proposed to cause cardiotoxicity [20, 21]. Pathologic findings 
in chronic anthracycline cardiotoxicity include loss of myofibrils 
within myocytes, vascular and mitochondrial degeneration and 
interstitial fibrosis [22, 23]. As myocytes undergo apoptosis and 
their cardiac growth responses to increasing somatic growth in chil-
dren become inadequate, the LV walls become thinner, and the 
remaining cells compensate by becoming hypertrophic to create an 
LV mass that is as close as possible to normal for body surface 
area. This compensation means that many anthracycline-treated 
survivors with abnormal LV structure and function by echocardi-
ography may show only histologic evidence of individual cardio-
myocyte hypertrophy [24]. Anthracycline damage to all cardiac 
structures may begin with the first anthracycline dose [25]. Car-
diotoxicity that occurs soon after anthracycline administration may 
be a harbinger of later toxicity; relatively little data exist about late-
onset anthracycline cardiotoxicity in long-term survivors of adult 
malignancy [24]. 
 Various methods have been recommended for the monitoring of 
cardiotoxicity in oncology. Recently, the applicability of cardiac 
troponins and creatine kinase MB CK-MB mass has been investi-
gated in this setting and the results of clinical studies are inconsis-
tent [26]. Horacek et al. [27] suggest that GPBB could be a new 
promising marker for detection of anthracycline-related cardiotox-
icity and probably superior to cardiac troponins.  
Doxorubicin 
 The most commonly used anthracycline is doxorubicin. 
Doxorubicin has a broad spectrum activity against both haemato-
logical cancers and solid tumours [28]. Doxorubicin cardiotoxicity 
is one of the most serious side effects of the cyclophosphamide, 
doxorubicin, vincristine, and prednisone chemotherapy, regimen, 
especially among elderly patients. In the CEOP regimen, epirubicin 
was substituted for doxorubicin to reduce cardiotoxicity. It is used 
in the treatment of acute leukaemias, both lymphocytic and myelo-
genous, [29] non-Hodgkin’s lymphoma, [30] and Hodgkin’s disease 
[31]. Doxorubicin is also effective against nonhaematological tu-
Table 1. Cardiac Toxicity and Proposed Prevention for the Most Commonly Used Chemo and Biological Therapy in Blood Cancers 
Type of Blood Cancer Protocols’ Acromynous Type of Cardiotoxicity Prevention of Cardiotoxicity 
Acute Myeloid Leukemia 3+7 congestive heart failure cardioprotective agents in conjunction with anthracyclines 
Acute Lymphoid Leukemia  congestive heart failure cardioprotective agents in conjunction with anthracyclines 
Chronic Myeloid Leukemia Imatinib-dasatinb-nilotinib Oedema, dyspnea, left ventricu-
lar contractile dysfunction 
Careful cardiac monitoring 
Non Hodgkin Lymphomas R-CHOP supraventricular arytmia, tachy-
cardia, complete atrioventricular 
block 
Careful cardiac monitoring 
 R-CVP supraventricular arytmia, tachy-
cardia, complete atrioventricular 
bloc 
Careful cardiac monitoring 
 R-ICE supraventricular arytmia, tachy-
cardia 
Careful cardiac monitoring 
Chronic Lymphatic Leukemia FCR Acute onset heart failure and/or 
myocarditis 
Diuretics, angiotensin-converting enzyme inhibitor 
Hodgking lymphoma ABVD Acute onset heart failure Use of liposomal encapsulation 
Myeloma MP bradycardia  
 MP-THAL bradycardia  
 MPV bradycardia  
 THAL-DEX bradycardia  
 LEN atrial fibrillation  
3+7: Cytarabine 100 mg/m2 i. v. , Daunorubicin 45 mg/m2 i. v.  
R-CHOP: Rituximab 375 mg/m2 i. v. , - Cyclophosphamide 750 mg/m2 i. v. - Adriamycin 50 mg/m2 i. v. ; Prednisone 100 mg/m2 oral 
R-CVP: Rituximab 375 mg/m2 EV; Cyclophosphamide 750 mg/m2 EV; Vincristine 1. 4 mg/m2 i. v. ,  
Prednisone 100 mg/m2 oral 
R-ICE: Rituximab 375 mg/m2 i. v. ; Ifosfamide 1 gr/m2 (dmax 1, 75g) i. v. ; Cisplatin 25 mg/m2 i. v. ; Etoposide 100 mg/m2 i. v.  
FCR: Rituximab 375 mg/m2(day 1); Fludarabine 25 mg/m2; Cyclophosphamide 750 mg/m2  
ABVD: Adriamycin 25mg/m2 i. v. ; Bleomycin 10U/m2 EV; Vinblastine 6 mg/m2 i. v. ; Dacarbazine 375 mg/m2 i. v.  
LEN: lenalidomide 
MP: Melphalan 10 mg/m2 oral; Prednisone 60 mg/m2 oral 
MP/Thal: Melphalan 10 mg/m2 oral; Prednisone 60 mg/m2 oral; Thalidomide 50-100 mg oral 
MPV: Melphalan 9 mg/m2 oral; Prednisone 60 mg/m2 oral; Bortezomib 1, 3 mg/m2 i. v.  
Thal/Dex: Thalidomide 200 mg; Dexamethasone 40 mg 
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mours, e. g. osteogenic sarcoma, [32] Ewing’s sarcoma and Wilm’s 
tumour, [33] and breast carcinoma [34].  
 The risk of doxorubicin induced congestive heart failure (CHF) 
increases with the cumulative dose. Cardiotoxicity is reported in 
14% to 49% of patients treated for lymphoma, and among patients 
with NHL, the risk of CHF increases with the patient’s age and 
history of coronary heart disease, valvular heart disease, hyperten-
sion, diabetes, cigarette smoking, or obesity [35, 36].  
 Hershman et Colleogues [37] found that hypertension, a known 
risk factor for CHF, increases the risk of doxorubicin-related car-
diotoxicity. Authors also demonstrated that selection factors may 
appropriately contribute to the receipt of doxorubicin-based chemo-
therapy in the elderly. Although late cardiac toxicity is increased 
with both longer duration of doxorubicin therapy and known pre-
dictors of HD, such as advanced age, comorbid conditions, prior 
heart disease, and diabetes, these other risks did not seem to poten-
tiate the cardiotoxic effects of doxorubicin in Elderly Patients With 
Diffuse B-Cell Non-Hodgkin’s Lymphoma.  
2. How to Prevent Anthracyclines Cardiotoxicity 
 To maximize the beneficial effects of anthracyclines, much 
effort has been spent devising new strategies to decrease or prevent 
their cardiotoxic effects. In addition to various dosing schedules 
aimed at lowering peak plasma concentrations, an alternative strat-
egy has been liposomal encapsulation. The most commonly used 
formulation is pegylated liposomal doxorubicin (Doxil). Which has 
a reduced tendency to accumulate in myocardial cells, with a resul-
tant decrease in cardiotoxicity. Unlike traditional doxorubicin, pe-
gylated doxorubicin has lower concentrations of free drug in the 
bloodstream and limited concentration in myocardial cells [38].  
 The non-pegylated liposomal anthracycline formulation 
(Myocet) had at least three randomized controlled trials with prom-
ising cardioprotective results. Myocet improves the therapeutic 
index of doxorubicin by significantly reducing cardiotoxicity and 
grade 4 neutropenia and provides comparable antitumour efficacy, 
when used in combination with cyclophosphamide as first-line 
therapy for MBC [39].  
 In recent years, novel anthracycline analogues have been devel-
oped with the hope that they will be as effective as conventional 
anthracyclines, but without the risk of cardiotoxicity. Idarubicin, a 
synthetic derivative of daunorubicin, is more lipophilic and has a 
longer half-life than danorubicin [40]. It is more lipophilic and can 
be administered orally as well as intravenously. Its main metabolite, 
idarubicinol, is as active as the parent drug. Idarubicin is effective 
at treating lymphoid and myeloid leukaemias, non-Hodgkin’s lym-
phoma and advanced breast cancer. Similar to epirubicin, idarubicin 
causes less cardiotoxicity than doxorubicin [41].  
 Another approach to preventing anthracycline-induced car-
diotoxicity is to use cardioprotective agents in conjunction with 
anthracyclines to mitigate their cardiotoxic effects. Dexrazoxane 
(ICRF-187) is a cardioprotective agent approved by the FDA. It is a 
bispiperazine, a nonpolar derivative of ethylenediamintetraacetic 
acid and a water-soluble positive enantiomer of the racemic drug 
razoxane. The suggestion that Fe plays an important role in anthra-
cycline cardiotoxicity has been strengthened by observation that the 
chelator, dexrazoxane (ICRF-187), has a potent cardioprotective 
effect [42]. Despite the beneficial effects of dexrazoxane, concerns 
exist about the lack of information on its effect on late onset pro-
gressive cardiomyopathy, the lack of conclusive evidence that it 
reduces overall morbidity and mortality in paediatric patients, and 
its possible interference with the antitumour efficacy of anthracy-
clines [39].  
 
 
 
ALKYLATING AGENTS 
1. Cyclophosphamide 
 Cyclophosphamide (CY) is a non-cell-cycle-specific alkylating 
agent. It is a broadly active antineoplastic and immunosuppressant 
agent used in combination chemotherapy for non-Hodgkin’s lym-
phoma, leukaemia, Hodgkin’s disease, Burkitt’s lymphoma, multi-
ple myeloma, endometrial cancer, lung cancer and breast cancer 
[2]. Cardiotoxicity due to CY was reported in 1972 as a complica-
tion of bone marrow transplantation [43]. CY causes a direct dam-
age to the vascular endothelium, followed by transudation of the 
toxic metabolite and the resulting damage to myocytes, interstitial 
haemorrhage, odema, and intercapillary microthrombi responsible 
for ischaemic myocardial damage [44]. Cardiac toxicity caused by 
CY seems to be due to pharmacokinetics and metabolism of the 
drug showing tenfold interindividual variation, most probably be-
cause of the impact of genetic polymorphism on the activity of liver 
microsomal enzymes [39]. In contrast to doxorubicin-induced car-
diotoxicity, high-dose CY causes acute cardiac dysfunction that is 
independent of cumulative dose. CY doses greater than 1. 5 g/m2 
may be associated with cardiotoxic risk [40]. Cardiac toxicity is 
manifested by acute on set heart failure and/or myocarditis occur-
ring within 1-10 days after the administration of the first dose of 
CY. Some reports indicated that prior radiation therapy to the medi-
astinum or chest wall is an independent predictor of cardiotoxicity 
in patients with lymphoma undergoing high-dose chemotherapy 
[45]. A total dose ranging from 180 to 200 mg/kg over 2 to 4 days 
has been reported to cause symptomatic cardiomyopathy [46]. 
However, a dose as low as 120 mg/kg may also result in cardiotox-
icity.  
 Goldberg et al, found that doses based on body surface area 
rather than body weight correlate well with incidence of cyclophos-
phamide-induced cardiotoxicity [47]. The fact that young children 
have a relatively higher body surface area probably explains the 
lower incidence and severity of cyclophosphamide-induced car-
diotoxicity in them compared to adolescents and adults [47]. Sev-
eral widely employed combinations of High-Dose (HD) cyclophos-
phamide are not associated with an increased risk of cardiotoxicity 
over single-agent HD cyclophosphamide. However, the risk for HD 
cyclophosphamide- associated cardiac toxicity may be increased by 
the concomitant administration of cytarabine or mitoxantrone [48].  
 Very little is known about cardiac toxicity of the treatment 
regimen with CY as part of stem cell collection followed by two 
autologous HSCT treatments with myeloablative dosages of MEL 
given in a very short time. Samo et al. [49] showed that MM pa-
tients treated with tandem autologous HSCT develop transient, 
mostly reversible and clinically non-overt neurohormonal activation 
of heart failure in each phase of treatment.  
2. How to Prevent Cyclofosfamide Cardiotoxicity 
 Although there are no specific predictive parameters of car-
diotoxicity, cardiac monitoring in high-risk patients undergoing 
high dose CY therapy may help to prevent serious cardiotoxicity 
[50]. It has been reported that cyclosporin-A, administered with 
CY, prevents cardiotoxicity [30], suggesting that CY induced car-
diotoxicity is associated with mitochondrial membrane permeability 
to Ca2+ and that cyclosporine-A may restore mitochondrial perme-
ability and prevent apoptosis of cardiomyocytes[51, 52]. Therapy 
with diuretics should be started in the first instance. The addition of 
an angiotensin-converting enzyme inhibitor in case of ECG and/or 
two-dimensional echocardiogram (2D echo) evidence of impaired 
left ventricular contraction, the patient not being hypotensive, 
should be considered according to established guidelines [53].  
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B. NON CHEMOTHERAPIC AGENTS 
Tyrosin-Kinase Inhibitors (Imatinib, Dasatinib and Nilotinib) 
 Imatinib, an example of a molecular-targeted drug, has revolu-
tionised treatment of chronic myeloid leukaemia (CML), and is 
now recommended as standard treatment for the accelerated and 
chronic-phase disease [54]. The cardiac effect of imatinib is contro-
versial [54, 55]. Cardiac toxicity may range from asymptomatic 
subclinical abnormalities such as electrocardiographic changes and 
left ventricular ejection fraction decline to life threatening events 
like congestive heart failure and acute coronary syndrome.  
 Clinical trials of the agent have reported a relatively high inci-
dence of peripheral odema (63-66%), some of which has been clas-
sified as severe (4-5%). In addition, dyspnea has been reported in 
12-16% of treated individuals and has been classified as severe in 
4-5% [56]. Cardiomyocytes from subjects who are being treated 
with imatinib appear to have endoplasmic reticula that have been 
activated in response to cellular stress, collapsed mitochondrial 
membrane potential, reduced ATP content, and to be more prone to 
cell death [56]. However, whether the observed cardiomyocyte cell 
damage represents clinical cardiotoxicity is still controversial [57], 
as is the role of the protooncogene abl (a target of imatinib and 
similar compounds) in the physiology of the cardiomyocyte [56, 
57].  
 Kerkela et al. [58] report ten individuals who developed severe 
congestive heart failure while on imatinib and they show that 
imatinib-treated mice develop left ventricular contractile dysfunc-
tion. With imatinib treatment, cardiomyocytes in culture show acti-
vation of the endoplasmic reticulum (ER) stress response, collapse 
of the mitochondrial membrane potential, release of cytochrome c 
into the cytosol, reduction in cellular ATP content and cell death.  
 It has been reported that individuals treated with imatinib de-
veloped severe CHF due to myocyte contractile dysfunction [58]. 
All patients had their left ventricular ejection fraction (LVEF) cal-
culated by radionuclide imaging before the onset of treatment and 
after they developed symptoms of heart failure. In a series of 103 
patients with CML treated with imatinib[59] and 57 patients with 
CML not treated with imatinib, no statistical difference was ob-
served between the two groups regarding cardiac symptoms and 
signs, BNP levels, and echocardiographic measurements. However, 
peripheral oedema was more frequent in the group that received 
imatinib.  
 The early detection and application of the treatment for left 
ventricular dysfunction is of key importance for the prevention of 
irreversible myocardial injury. Careful cardiac monitoring and as-
sessment by a cardiologist throughout the course of treatment with 
those TKIs that exert cardiac toxic effect is of primary importance 
[3].  
 Dasatinib is a multitargeted kinase inhibitor against Bcr-Abl, 
cKit, PDGFR-a and b and the SRC family of kinases. Although 
clinical trials report high rates of peripheral oedema [60], only a 2% 
incidence of congestive heart failure as well as arrhythmias (includ-
ing tachycardia) has been associated with Dasatinib treatment [61]. 
Nilotinib is an inhibitor of Bcr-Abl, c-Kit and PDGFRa and b re-
ceptors; Except for QT prolongation on ECG, no other cardiac 
event has been reported [62].  
RITUXIMAB 
 Rituximab is a recombinant, chimeric anti-CD20 antibody that 
has emerged in recent years as an effective therapy for non-
Hodgkin’s lymphoma (NHL) and other B-cell malignancies [63]. 
Rituximab binds to the CD20 antigen expressed on almost all ma-
lignant B-cells and leads to their destruction; it is used usually in 
combination of various protocols of chemotherapy. Treatment with 
rituximab is generally well tolerated and can be combined with 
chemotherapy, improving response rate, response duration, and in 
some cases overall survival of patients with B-cell lymphomas.  
 The cardiotoxicity of Rituximab has been reported when admin-
istered with chemotherapy or as monotherapy. Cardiac complica-
tions involving the conduction system, such as supraventricular 
arrhythmia and tachycardia, frequently occur in rituximab/ CHOP 
therapy [64]. In these cases, it may be difficult to correctly deter-
mine which medication, rituximab or anthracycline, cause them. 
Some authors reported a frequency of cardiac toxicity, manifested 
as grade 3 and 4 arrhythmias and supraventricular arrhythmias 
(such as tachycardia and auricular fibrillation or flutter) as high as 
5. 9% when rituximab is used with CHOP (cyclophosphamide, 
doxorubicin, oncovin, and prednisone) versus a level of 1. 0% in 
patients who received chemotherapy alone [64]. During events of 
heart failure, higher levels of tumour necrosis factor- (TNF-) and 
interleukin- 6 (IL-6) were observed, though this association might 
be related to a greater extent to their vasodilating compensating 
effect, unable to repair the endothelial damage seen in these situa-
tions [65].  
 Other clinical experiences reported unusual cardiac toxicity 
during rituximab treatment. Cervera et al. [66] described a case of 
elderly woman treated with Rituximab in monotherapy who experi-
enced a complete atrioventricular block (CAVB) after the fifth ad-
ministration. Authors explained such event likely due to cytokine 
release by anti-CD 20. Arai Y et al. [67] report herein a patient with 
mantle cell lymphoma (MCL) presenting ventricular tachycardia 
during infusion of rituximab. He received rituximab intravenously 
at a dose of 375 mg/m2 weekly for eight consecutive courses. Dur-
ing the rituximab infusion, electrocardiogram monitoring was per-
formed. The second to seventh courses were eventless, although the 
first course was associated with pyrexia. However, transient ven-
tricular tachycardia occurred during the infusion of the eighth 
course. Foran reported that 7% of 131 patients with MCL, immuno-
cytoma, or small B-cell lymphocytic lymphoma who received ri-
tuximab as a single agent developed arrhythmia, including brady-
cardia, atrial fibrillation, tachycardia, and premature ventricular 
complexes [68]. Ponterucha et al. [69] (reported the 1st case report 
of symptomatic polymorphic ventricular tachycardia (VT) which 
occurred during an initial infusion of rituximab.  
 However, such findings were not reported by others. Kilickap et 
al. [70] evaluated whether the addition of rituximab to an anthracy-
cline-based regimen (CHOP) resulted in an increase in subclinical 
cardiac toxicity. Patients who were to receive CHOP or rituximab 
plus CHOP (R-CHOP) combination chemotherapy with a diagnosis 
of NHL were included in the study. Diastolic and systolic cardiac 
parameters, by using two-dimensional echocardiography, conven-
tional pulsed-wave Doppler echocardiography and tissue Doppler 
echocardiography, were monitored before and after chemotherapy. 
There were 28 (M/F; 14/14) patients on CHOP and 33 (M/F; 16/17) 
patients on R-CHOP; Parameters of systolic function such as LVEF 
and FS did not significantly change in any patient. Doppler parame-
ters of diastolic function such as lateral E and septal E velocity of 
mitral annulus decreased significantly after therapy (P < 0. 001). 
However, the decrease in diastolic function was similar in both 
arms (P > 0. 05). The addition of rituximab to CHOP chemotherapy 
does not significantly increase the risk of doxorubicin induced car-
diotoxicity during administration and in the follow-up. Siano M. et 
colleagues have shown that the administration of rituximab with a 
maximal dose of 700 mg over 60 minutes without steroid premedi-
cation is feasible and safe, provided one well-tolerated rituximab 
dose had been given in the previous 3 months. Patients with any 
type of B-cell lymphoma were eligible; Cohorts of at least three 
patients were assigned to rituximab with or without concomitant 
chemotherapy. An extensive cardiologic evaluation was done con-
comitantly to evaluate whether the increased infusion rate induced 
cardiotoxicity. Only one patient showed totally asymptomatic ECG 
alterations (repolarization disorder) of still uncertain origin. This 
alteration was correlated to rituximab infusion—although a coro-
nary heart disease was not formally ruled out—and after a reduction 
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of the infusion rate, no further ECG alterations were reported. In all 
cases, normal troponin values along with unchanged echocardio-
grams and Holter ECGs confirmed the lack of cardiotoxic effect of 
a fast infusion rate. Zaja et al. [71] investigate rituximab efficacy in 
previously untreated adult ITP patients with a platelet count of 20 x 
10(9)/L or less. One hundred three patients were randomly assigned 
to receive 40 mg/d dexamethasone for 4 days with or without 375 
mg/m2 rituximab weekly for 4 weeks. One patient experienced 
supraventricular tachycardia during the first administration of ri-
tuximab, and 1 patient experienced seizure during the salvage 
treatment: both were probably related to study drug, and both pa-
tients were discontinued from the study. One patient with a previ-
ous history of vascular disease had a transitory ischaemic attack not 
related to study drug during salvage therapy.  
PROTEASOME INHIBITORS 
 Bortezomib (Velcade, formerly PS-341) is a selective protea-
some inhibitor that shows strong activity in vitro and in vivo against 
solid and haematologic malignancies [72]. Preclinical study results 
show that bortezomib suppresses tumour cell growth, induces apop-
tosis, overcomes resistance to standard chemotherapy agents and 
radiation therapy, and inhibits angiogenesis. Phase I study results 
established the antitumour activity of bortezomib, administered 
alone or in combination with standard chemotherapy agents, in 
patients with advanced haematologic malignancies or solid tu-
mours, usually without additive toxicities [73].  
 Enrico O et al. [74] reported cardiotoxicity in haematological 
patients treated with bortezomib. Eight (11. 6 %) of 69 patients 
developed serious cardiac side effects requiring medication, hospi-
talisation or an implant of a pacemaker. All eight patients who ex-
perienced cardiotoxicity underwent at least four cycles of borte-
zomib, strengthening the hypothesis of a direct connection with the 
drug. Authors explained that bortezomib may simultaneously cause 
atherosclerotic plaque progression and tendency to rupture, and 
facilitate ischaemic heart complications by reducing/abrogating 
myocardial preconditioning.  
 Takamatsu et al. [75] reported a case of a 79-year-old female 
patient with multiple myeloma who had no prior cardiac disease 
history developed an acute myocardial infarction on day 5 after 
receiving bortezomib and dexamethasone (BD). After treatment of 
coronary stenoses by stents, she received another course of BD 
therapy and developed angina pectoris on day 5 after the therapy.  
 Additionally, there is much experimental evidence to support 
the crucial role of a deficient proteasome activity in impairing car-
diac function by several mechanisms, the most important of which 
is putatively the accumulation of unfolded, damaged and unde-
graded proteins inside myocytes (as extensively reviewed by Willis 
& Patterson, 2006).  
 Zheng Hu et al. [76] tested the therapeutic efficacies as well as 
adverse effects of low dose imatinib mesyllate (IM) in combination 
with proteasome inhibitor, Bortezomib (BOR) or proteasome in-
hibitor I (PSI), in two CML murine models, and investigated possi-
ble mechanisms of action on chronic myeloid leukaemia (CML) 
cells. Their results demonstrated that low dose IM in combination 
with BOR exerted satisfactory efficacy in prolongation of life span 
and inhibition of tumour growth in mice, and did not cause car-
diotoxicity or body weight loss.  
ANTIANGIOGENETIC DRUGS 
Thalidomide, Lenalidomide, Pomalidomide 
 Angiogenesis is a vital process resulting in the formation of 
new blood vessels [77]. While several studies have found moderate 
improvements when treated with angiogenesis inhibitors, greater 
success is being seen when the inhibition of angiogenesis is com-
bined with other traditional forms of available therapy [78]. Tha-
lidomide, an immunomodulatory and antiangiogenic agent, is useful 
in the treatment of some haematologic (mainly myeloma and other 
plasma-cell related disorders) and oncologic diseases. Thalidomide-
mechanisms of action are multifactorial based on immunomodula-
tion, antiangiogenesis and cytokines regulation, particularly tumour 
necrosis factor-alpha. It has been reported that up to 6. 8% of tha-
lidomide-treated patients present bradycardia [79].  
  Lopez-de la cruz et al. [78] reported their experience with Tha-
lidomide in patients with haematologic diseases. In a 34-month 
period, 33 patients with different haematologic diseases (multiple 
myeloma [MM], 20; myelodysplastic syndrome, eight; Walden-
ström macroglobulinemia, two; non-Hodgkin's lymphoma, two; 
malignant histiocytosis, one) were treated with thalidomide. Of 
them, five (15. 1%) had bradycardia, all with MM. Bradycardia was 
detected with a daily thalidomide dose ranging from 100 to 300 mg 
and the time patients received thalidomide before cardiac event 
went from one to 18 months. Palladini et al. [79] evaluated the 
combination of thalidomide and intermediate-dose dexamethasone 
(T-Dex) in 31 patients with AL who did not respond to, or whose 
disease relapsed after, first-line therapy. In this study, symptomatic 
bradycardia emerged as a common (26%) adverse reaction to tha-
lidomide in patients with AL. Bradycardia was reported in 1 of 16 
patients by the Boston group [80]) and in 1 of 12 patients by the 
Mayo Clinic Group [81]. A recent retrospective study performed on 
96 myeloma patients treated with thalidomide showed a decrease in 
heart rate below 60 beats/min in 53% of patients and symptomatic 
bradycardia in 19% of patients, 23 which initially went unrecog-
nized because studying the heart rate was not within the objectives 
of the original Trial [82].  
 Interestingly, despite these findings, few studies suggested the 
role for thalidomide in the management of chronic heart failure 
(CHF) in addition to traditional cardiovascular medications. In fact, 
Thalidomide is a drug with potential immunomodulating and ma-
trix-stabilizing properties, that can improve left ventricular (LV) 
function in patients with CHF secondary to idiopathic dilated car-
diomyopathy (IDCM) or coronary artery disease (CAD). Gullestad 
et al. [83] reported in their double-blind, placebo controlled study, 
that thalidomide increases LVEF and that these changes are accom-
panied by a decrease in LVEDV, suggesting that thalidomide can 
alleviate adverse myocardial remodelling and improve LV function 
in CHF. Importantly, this improvement in LV function occurred in 
the patients who were clinically stable and who, in the majority of 
cases, were receiving angiotensin-converting enzyme inhibitors or 
angiotensin II and_-blockers in addition to diuretics.  
 The use of thalidomide is limited by adverse effects of sedation, 
constipation, neuropathy and thromboembolism. In order to over-
pass such side-effects thus producing more potent and less toxic 
immunomodulators, thalidomide chemical structure has been modi-
fied and new compounds such as lenalidomide and pomalidomide 
were produced. Lenalidomide is approved by the US FDA for the 
treatment of patients with low-risk myelodysplastic syndrome 
(MDS) with deletion 5q cytogenetic abnormality [84]. Lenalido-
mide, unlike thalidomide, does not appear to cause peripheral neu-
ropathy, but it does provoke cardiac arrhythmia such as atrial fibril-
lation (18% versus 11% with placebo) and had severe haematologi-
cal effects [85]. In two randomised, doubleblind, multicenter stud-
ies, the combination of lenalidomide and dexamethasone (LD) was 
compared with placebo and dexamethasone (PD) in patients with 
MM who had received at least one prior therapy [86]. The most 
clinically relevant grade 3 and 4 adverse events that occurred more 
frequently in the LD arm were neutropenia, thrombocytopenia, 
deep vein thrombosis, pulmonary embolism, and atrial fibrillation.  
 Immunomudulatory drugs (IMiDs) including thalidomide and 
lenalidomide have a proven role in the treatment of multiple mye-
loma (MM) and have significant activity in myelofibrosis (MF). 
Pomalidomide is the newest IMiD and appears to be promising for 
use in both MM and MF. IMiDs are hypothesised to act through 
multiple mechanisms including effects on angiogenesis and cyto-
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kine production [87]. Pomalidomide (POM) is an IMID signifi-
cantly more potent than thalidomide, but without the limiting tox-
icities of neuropathy or sedation and cardiotoxicity.  
CONCLUSIONS 
 Introduction of high-dose (HD) chemotherapy has improved the 
clinical outcome of patients with chemosensitive tumours, such as 
non-Hodgkin’s lymphoma, Hodgkin’s disease, multiple myeloma 
and leukaemias [88, 89]. However, cardiac toxicity has been fre-
quently reported, particularly in HD cyclophosphamide-containing 
regimens, thus limiting their use especially in older patients.  
Management of cardiac toxicity of chemotherapeutic agents is cru-
cial since the increasing pool of long-term haematological cancer 
survivors. Preventative strategies that have met with some success 
have included the use of less cardiotoxic analogues such as epirubi-
cin and liposomal anthracycline preparations. The role of investiga-
tional markers of myocardial injury, such as troponin T or brain 
natriuretic peptide, remains of great interest but still without robust 
evidences. In table 1 cardiotoxicity and its prevention in the most 
common antineoplastic regimens are reported. 
 The development of the so-called "targeted therapies", particu-
larly drugs that inhibit the activity of tyrosine kinases, has become a 
remarkable progress in the treatment of neoplastic diseases. Recent 
data has shown that some of these therapies are associated with 
certain cardiotoxicity ranging from asymptomatic mild left ven-
tricular dysfunction to congestive heart failure through different 
mechanisms.  
 In conclusion, old and new therapies for managing haemato-
logical malignancies are associated with cardiotoxicity; knowledge 
of any potential effect on cardiac function is crucial for the choice 
of the best regimen specially in elderly patients.  
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